Definizione di farmaco innovativo: rivisitazione in un contesto di risorse limitate

Motola D, De Ponti F, Rossi P, et al. Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003. Br J Clin Pharmacol 2005; 59: 475–8

AIFA. Documento approvato dalla Commissione Tecnico Scientifica il 10 luglio 2007. Scaricabile da: http://www.agenziafarmaco.gov.it/sites/default/files/documento_inte grale.pdf

Pearson SD, Rawlins MD. Quality, innovation, and value for money: NICE and the British National Health Service. JAMA 2005; 294: 2618–22

Claxton K, Briggs A, Buxton MJ, et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 2008; 336: 251–4

Messori A, Santarlasci B, Trippoli S, et al. Controvalore economico del farmaco e beneficio clinico: stato dell’arte della metodologia e applicazione di un algoritmo farmacoeconomico. Pharmacoeconomics-Italian Research Articles 2003; 5: 53–67

Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005; 331: 897–900

Fadda V, Maratea D, Trippoli S, et al. Network meta-analysis. Results can be summarised in a simple figure. BMJ 2011 Mar 23; 342: d1555. doi: 10.1136/bmj.d1555

Passaro D, Fadda V, Maratea D, et al. Anti-platelet treatments in acute coronary syndrome: simplified network meta-analysis. Int J Cardiology 2011; 150: 364–7

Fadda V, Maratea D, Trippoli S, et al. Treatments for macular degeneration: summarising evidence using network meta-analysis. Br J Ophthalmol 2011; 95: 1476–7

Maratea D, Del Santo F, Trippoli S, et al. Indirect comparison of bortezomib vs thalidomide in myeloma patients ineligible for transplantation (E-Letter). Blood 2011 available at http://bloodjournal.hematologylibrary.org/content/116/9/1405.full/reply#bloodjournal_el_1430